Get started

QBIO

$QBIO Bull Flag Pattern with Explosive Upside PotentialQBIO has a float of just 18.6 million shares. The stock is trading on a stick of dynamite. We have seen this explosive character several times in the past few months. This stock can take off like a rocket. On three separate occasions, we have seen QBIO shares leap by 50-100% in less than a week in the past 6 months. Right now, we are seeing a “bullish flag pattern” following the burst to the upside that hit toward the end of March. That sprint has been consolidated in a healthy manner at this point, and a follow-through move to the upside could be primed. About QBIO QBIO (Q BioMed Inc.) is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company’s ace offering is Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. Q BioMed Inc. has a research partnership with Mannin Research Inc. for the development of therapeutics to treat a variety of vascular diseases, including the new coronavirus. Q BioMed Inc. is a biotech acceleration and commercial-stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏. Key Points: • QBIO is moving into commercial-stage for its FDA-approved cancer drug, Strontium89.. ie, here comes the payoff • QBIO has a small trading float of just 18.6M, which suggests the stock could launch higher on any additional influx of interest. • QBIO is also developing a key potential treatment for COVID-19 and other infectious diseases, including influenza • QBIO is coming off an RSI trough under 30 in mid-March, pointing to a massively oversold stock now heading back the other way, and consolidating in a nice “Bullish Flag” breakout pattern • QBIO is planning on uplisting to the Nasdaq, which is often a major bull catalyst for OTC stocks
OTC:QBIOLong
by GregFolin
$QBIO is on a Wild Ride with Buy-the-Dip SignalsQBIO Q BioMed Inc. (OTCMKTS:QBIO) is another roller coaster in play on the OTC. This is an interesting player in the small float small-cap biotech growth space that has projects in motion to attack a major growth market (non-verbal learning disorder) with little competition and big potential. And the chart is screaming that smart traders and investors should do some due diligence here – which is why we put in front of you today. The company just announced that its technology research partner Mannin Research Inc. presented positive data on a potential new treatment for acute kidney injury (AKI). According to the release, “The data was presented at the American Society for Nephrology 2019 Annual Meeting held in Washington DC. In the US alone, the cost of hospitalizations for patients with complications arising from AKI can range between $5.4 and $24.0 billion1. There is a significant opportunity to advance a therapeutic solution to treat AK and address a patient population that contributes to 20% of all hospitalizations in the US2. Current treatments for AKI are mainly supportive and do not treat the underlying condition.” Read More at: dailytrendingstocks.com
OTC:QBIO
by GregFolin
$QBIO back on high alert; shows +68pct Upside Potential!===================== QBIO (Q BioMed Inc.) Alert Price: $2.00 Float: 9.2M Chart Analysis Investor Presentation Fact Sheet Shareholder Update Corporate Update Video ======================== Members, It was an ugly day on Wall St. to say the least. The Dow Jones Industrial Average dropped 220.77 points to 25,169.53 as Apple and DowDuPont led the decline. The S&P 500 pulled back 0.94 percent to close at 2,706.05, led lower by the energy and tech sectors. The Nasdaq Composite lagged, sliding about 1.2 percent to 7,288.35. With the global economy in question, we believe that the smart money will once again be flowing back into the microcaps. This is great news for our members, as we are always on the hunt for the next breakout microcap company. We wanted to end this week on a high note, and what better way to do that than going with a microcap company that has already delivered some nice returns for our members in the past. That being said, we ask that you once again turn your immediate attention to QBIO (Q BioMed Inc.). We first brought this biomedical acceleration and development company to your attention on January 22nd. Those who acted on that buy call were rewarded to the tune of over +37% in multi-day gains as shares rose from our $1.77 alert price to a high of $2.43. We've been keeping a close eye on QBIO since then, and are now once again issuing a buy call to our members. QBIO appears to be oversold at the moment, and we believe that now could be the perfect time to start building a position. First off, the Company has been getting a lot of press as of late. Chairman and CEO, Denis Corin recently held an interview with FinancialBuzz from the floor of the NASDAQ MarketSite at Times Square New York City. During the interview, Mr. Corin shared his vision of the Company's growth and why he believes 2019 and beyond are essential years for QBIO. The interview provides unique insight into the Company's latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value. FinancialBuzz.com is a respected source in the financial news media space located on Wall Street, and the interview is a much watch for anyone interested in QBIO. QBIO also announced that CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at the BIO CEO & Investor Conference on February 11th -12th, 2019 in New York City. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. This is exactly what we meant when we stated in our previous email that the QBIO's management team was committed to its success and growth. With all these steps in the right direction, we were surprised by the recent pull back for QBIO. The company has several bullish catalysts working in its favor that we believe will help make it a significant winner once again for our members: The biotech sector as a whole has been on fire, with the IBB ETF up nearly +20% since December 24th. QBIO's strong corporate leadership led by CEO Denis Coran. We've done our very own chart analysis on QBIO, and see as much as +68% in immediate upside potential! Strong buzz on Twitter A growing pipeline and strategy that mitigates risk & drives shareholder value. Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets. QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be $20M-$40m p/a in year 3. QBIO's QBM-001 treatment for pediatric non-verbal disorder has $5B in global market potential. QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020. Technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery. Now what has us really excited about QBIO, is what we heard during CEO Denis Coran's audio interview with SmallCapVoice.com on January 15th. At around the twelve minute mark, Mr. Coran hints at an upcoming FDA approval for QBIO's south Texas manufacturing facility. Once approved QBIO can start producing Metastron™ commercially for sale in the U.S. and then internationally! This drug is a substantial opportunity for QBIO. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue! This would be huge news, and could have a major impact on QBIO's stock price. This is a great and informative interview, and it should get you excited about the incredible opportunity that QBIO presents you at the moment. We would also like to mention, that just like several of our past big winners, QBIO trades on the OTCQB Venture Marketplace. Securities trading on OTCQB have higher reporting and certification standards, which tends to lead to increased liquidity, investor confidence, as well as enhanced shareholder value. If you missed out on QBIO's previous +37% run, you may want to consider jumping on board this time around. As such, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST! About Q BioMed Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need. QBIO aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron. QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma. Q BioMed Unlocks Undiscovered Biomedical Value Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management Licenses or acquires the assets and works together to create valuation growth How Q BioMed Accelerates Biomedical Technology Development Unlocks capital in US public markets to fund the development of assets Makes liquid investments in high-value assets that can produce exponential returns Diversifies risk over several therapies in various stages of development and deploys performance-based capital only Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships Recent Developments Q BioMed Seeks Multi-billion Dollar Opportunity with New Glaucoma Treatment Candidate On January 25th, the Company announced that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery. CEO of Mannin Research, Dr. George Nikopoulos stated, "This collaboration is extremely important for us and Q BioMed, as well as the MAN-01 program. The Sheardown lab at McMaster University specializes in ophthalmic delivery systems. As we approach our Phase I clinical trial, having the renowned expertise and experience of Dr. Sheardown and her team working with us on delivering our small molecule candidates to the eye is important to our success." The main objective of the collaboration is to explore novel and better ways of delivering Mannin's small molecules to the eye to treat glaucoma. Using the formulation and drug delivery expertise of the Sheardown laboratory, the collaboration partners are focusing on increasing the compounds' ability to lower intra-ocular pressure to more effectively treat glaucoma. Q BioMed CEO Denis Corin commented, "Through this collaboration, we are also exploring the use of extended and sustained release formulations with the Mannin compounds for the treatment of other vascular related diseases, such as acute kidney injury, influenza, and myocardial ischemia. We expect the ophthalmic drug delivery data from this collaboration will inform our planned Investigational New Drug (IND) application with the U.S. FDA." About Dr. Sheardown Dr. Heather Sheardown holds a Tier 1 Canada Research Chair for Ophthalmic Biomaterials and Drug Delivery Systems. She is an expert in drug delivery, contact lens materials, (intraocular lenses) IOLs, polymer chemistry, and bioengineering in the ophthalmic space. Dr. Sheardown is a Professor in Chemical Engineering and the School of Biomedical Engineering at McMaster University and is cross-appointed with the School of Optometry at the University of Waterloo. Dr. Sheardown has gained an international reputation for her research on ophthalmic biomaterials, including her innovative work on the development of new materials for contact lenses and drug delivery applications. She has published more than 150 papers in top biomaterials journals, numerous book chapters on ocular materials and drug delivery and has several patents and patents pending on various ophthalmic materials. She has worked extensively with major ophthalmic materials companies including Vistakon, CIBA Vision, Coopervision and AMO, and is the Chief Scientific Officer for a spin-out company, 20/20 OptimEyes Technology. Dr. Sheardown has an active and vibrant research group of more than 10 graduate students and post-doctoral fellows. Projects in her laboratory involve the development of new polymeric materials and delivery systems for all areas of the eye. These projects are currently supported by C20/20, an Ontario Research Fund grant. This grant is enabling the commercial development of academic-derived technologies and supporting partnerships with corporate partners with co-development opportunities. Market Outlook The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022. Bone Metatases from Prostate and Breast Cancer 450,000 new breast and prostate cancer diagnoses each year 1 in 3 people will develop bone metastases from the spread of breast and prostate cancer Pediatric Non-Verbal Disorder Among the >60,000 US children who develop Autism Spectrum Disorders (ASD) every year, 20,000 become nonverbal and will have to rely on assisted living for the rest of their life. Liver Cancer 700,000 patients worldwide Short 1-year survival rate Estimated 39,230 adults in the US will be diagnosed every year Glaucoma 60 million patients worldwide 8 million with bilateral blindness Typically no early warning signs Therapy only slows progression, no cure Technical Analysis QBIO's stock price has been on a downtrend as of late, but we believe that the bottom is in, and that the upside potential far outweighs the downside risk from here. CEO Denis Coran addressed the stocks decline in his most recent shareholder update, and we feel confident that he and his management team are well on their way towards reversing this downtrend. QBIO is trading well off its 52-week high, with plenty of room to the upside. In fact, a run back to its 52-week high of $4.50 would represent a gain of over +125%! The float on QBIO is also very thin at just 9.2M, so don't be surprised if we see a big move from this ticker tomorrow. We've done our very own chart analysis on QBIO, and see as much as +68% in immediate upside potential! If you missed out on QBIO's previous +37% run, you may want to consider jumping on board this time around! We are urging all members to start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST! (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, The TopMarketGainers Team Don't Miss Our Next Huge Winner... Text 'GAINS' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. We have been previosuly compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
OTC:QBIOLong
by RedHotStocks
$QBIO is our New Low-float, BioTech Alert w/ MASSIVE UPSIDE!===================== QBIO (Q BioMed Inc.) Alert Price: $1.77 Float: 9.2M Investor Presentation Fact Sheet Shareholder Update Corporate Update Video ======================== Members, We hope you enjoyed the over +23% in realistic profit that Wednesday's alert provided. Earlier today, we told you that we had identified a company operating in the biotech space that looks primed and ready to breakout for some significant gains in the immediate future. Please turn your immediate attention to QBIO (Q BioMed Inc.). This biomedical acceleration and development company appears to be extremely undervalued and oversold at the moment, and we want our members to be on board for what we believe will be an epic bullish reversal in Q1 2019. The company has several bullish catalysts working in its favor that we believe will help make it a significant winner for our members: The biotech sector as a whole has been on fire, and is up over +20% since December 24th. Strong corporate leadership led by CEO Denis Coran. A growing pipeline and strategy that mitigates risk & drives shareholder value. Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets. QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be $20M-$40m p/a in year 3. QBIO's QBM-001 treatment for pediatric non-verbal disorder has $5B in global market potential. QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020. Now what has us really excited about QBIO, is what we heard during CEO Denis Coran's audio interview with SmallCapVoice.com on January 15th. At around the twelve minute mark, Mr. Coran hints at an upcoming FDA approval for QBIO's south Texas manufacturing facility. Once approved QBIO can start producing Metastron™ commercially for sale in the U.S. and then internationally! This drug is a substantial opportunity for QBIO. A very similar drug with a very narrow indication currently does almost $800 million a year in revenue! This would be huge news, and could have a major impact on QBIO's stock price. This is a great and informative interview, and it should get you excited about the incredible opportunity that QBIO presents you at the moment. We would also like to mention, that just like several of our past big winners, QBIO trades on the OTCQB Venture Marketplace. Securities trading on OTCQB have higher reporting and certification standards, which tends to lead to increased liquidity, investor confidence, as well as enhanced shareholder value. This has the potential to be our next big winner of Q1 2019. As such, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST! About Q BioMed Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need. QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma. Q BioMed Unlocks Undiscovered Biomedical Value Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management Licenses or acquires the assets and works together to create valuation growth How Q BioMed Accelerates Biomedical Technology Development Unlocks capital in US public markets to fund the development of assets Makes liquid investments in high-value assets that can produce exponential returns Diversifies risk over several therapies in various stages of development and deploys performance-based capital only Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships Recent Developments Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001 On Wednesday, QBIO announced that Pamela Ventola Phd, from Yale University has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD). Dr. Ventola serves as a clinical psychologist and assistant professor at Yale University's Child Study Center with a clinical and research focus in: behavioral treatment for autism spectrum disorders, Pivotal Response Treatment (PRT), biological markers of treatment response, and dissemination and implementation of treatment for ASD. Dr. Ventola also directs the Rare Disease and Pediatric Center of Excellence at Cogstate, a publicly traded company that supports pharmaceutical companies in clinical trial design, methodologies, and rater training services as it relates to cognitive and other clinical outcome assessments. Strategy and Clinical Trial Design Specialist Provides Expertise for the Clinical Trial Design and Regulatory Requirements of QBM-001 QBM-001 Developed to Treat a Pediatric Non-Verbal Disorder which impacts 18,000 children each year in the U.S and a similar amount in Europe. Market Outlook The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022. Bone Metatases from Prostate and Breast Cancer 450,000 new breast and prostate cancer diagnoses each year 1 in 3 people will develop bone metastases from the spread of breast and prostate cancer Pediatric Non-Verbal Disorder Among the >60,000 US children who develop Autism Spectrum Disorders (ASD) every year, 20,000 become nonverbal and will have to rely on assisted living for the rest of their life. Liver Cancer 700,000 patients worldwide Short 1-year survival rate Estimated 39,230 adults in the US will be diagnosed every year Glaucoma 60 million patients worldwide 8 million with bilateral blindness Typically no early warning signs Therapy only slows progression, no cure Technical Analysis QBIO's stock price has been on a downtrend as of late, but we believe that the bottom is in, and that the upside potential far outweighs the downside risk. CEO Denis Coran addressed the stocks decline in his most recent shareholder update, and we feel confident that he and his management team are well on their way towards reversing this downtrend. QBIO is trading well off its 52-week high, with plenty of room to the upside. In fact, a run back to its 52-week high of $4.50 would represent a gain of over +154%! The float on QBIO is also very thin at just $1.77, so don't be surprised if we see a big move from this ticker tomorrow. As we stated above, this could easily be our next big winner of Q1 2019. We are urging all members to start their research now, and consider grabbing up a position in QBIO tomorrow morning at 9:30AM EST! (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, The TopMarketGainers Team Don't Miss Our Next Huge Winner... Text 'GAINS' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct investor relations advertising and marketing for QBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
OTC:QBIOLong
by RedHotStocks